A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis

Neurology

Volumn 77, Issue 17, 2011, Pages 1611-1618

  Stein, M S ^a,b   Liu, Y ^c   Gray, O M ^d   Baker, J E ^a   Kolbe, S C ^e,f   Ditchfield, M R ^g,h   Egan, G F ^e,f   Mitchell, P J ^a,f   Harrison, L C ^a,b,f   Butzkueven, H ^a,e,f,h   Kilpatrick, T J ^a,e,f  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CRAIGAVON AREA HOSPITAL   (United Kingdom)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MONASH MEDICAL CENTRE   (Australia)

^h MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ERGOCALCIFEROL; GADOLINIUM; GLATIRAMER; INTERFERON;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SCORING SYSTEM; SINGLE BLIND PROCEDURE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 82955236170     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182343274     Document Type: Article

References (40)

1. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis [erratum 2004;79:890]. Am J Clin Nutr 2004;79:362-371. Review. (Pubitemid 41115577)
2. Freedman DM, Dosemeci M, Alavanja MC. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med 2000;57:418-421. (Pubitemid 30312755)
3. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838. (Pubitemid 44969183)
4. van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia J Neurol 2007;254:581-590. (Pubitemid 46781963)
5. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25- hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
6. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25- hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:152-157. (Pubitemid 351236545)
7. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618-624.
8. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009;132: 1146-1160.
9. Barnes MS, Bonham MP, Robson PJ, et al. Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 2007;13:670-672. (Pubitemid 46939536)
10. Holmøy T, Moen SM, Gundersen TA, et al. 25- hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler 2009;15: 1280-1285.
11. Embry AF, Snowdon LR, Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;48:271-272. (Pubitemid 30617053)
12. van Amerongen BM, Dijstra CD, Lips P, Polman CH. Multiple sclerosis and vitamin D: an update. Eur J Clin Nutr 2004;58:1095-1109. (Pubitemid 39172383)
13. Constantinescu CS, Hilliard B, Ventura E, et al. Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively. Clin Immunol 2001;98: 23-30.
14. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol 200;31:907-917.
15. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405-2411. (Pubitemid 30115468)
16. Nashold FE, Miller DJ, Hayes CE. 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2000;103:171-179. (Pubitemid 30079729)
17. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypoth 1986;21:193-200. (Pubitemid 17201931)
18. Burton JM, Kimball S, Vieth R, et al. A phase I/II doseescalation trial of vitamin D3 and calcium in multiple sclerosis [errata 2010;75:480, 2010;75:1029]. Neurology 2010;74:1852-1859.
19. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25- dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1294-1296. (Pubitemid 41208389)
20. Achiron A, Barak Y, Miron S, Izhak Y, Faibel M, Edelstein S. Alfacalcidol treatment in multiple sclerosis. Clin Neuropharmacol 2003;26:53. (Pubitemid 36397358)
21. Fleming JO, Hummel AL, Beinlich BR. Vitamin D treatment of relapsing-remitting multiple sclerosis (RRMS): a MRI-based pilot study. Neurology 2000;54:A338. Abstract.
22. Stein MS, Wark JD. An update on the therapeutic potential of vitamin D analogues. Expert Opin Investig Drugs 2003;12:825-840. (Pubitemid 36622190)
23. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
25. Hollis BW. Comparison of commercially available (125)Ibased RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem 2000;46:1657-1661.
26. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int 1998;8:222-230. (Pubitemid 28427071)
27. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007;86:645-651. (Pubitemid 47435831)
28. Reichel H, Koeffler HP, Norman AW. Synthesis in vitro of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by interferon-gamma- stimulated normal human bone marrow and alveolar macrophages. J Biol Chem 1987;262: 10931-10937. (Pubitemid 17122860)
29. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100-105. (Pubitemid 36733998)
30. Flicker L, MacInnis RJ, Stein MS, et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J Am Geriatr Soc 2005;53: 1881-1888. (Pubitemid 41826064)
31. Mawer EB, Jones G, Davies M, et al. Unique 24- hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans:24- hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. J Clin Endocrinol Metab 1998; 83:2156-2166. (Pubitemid 28496354)
32. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008;93:677-681. (Pubitemid 351398538)
33. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-890. (Pubitemid 28185166)
34. Hood GM. PopTools version 3.2.3. Available at: http:// www.poptools.org. Accessed April 2011.
35. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009;5:e1000369.
36. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003;134:128-132. (Pubitemid 36050838)
37. Stewart G. Multiple sclerosis and vitamin D: don't (yet) blame it on the sunshine. Brain 2009;132:1126-1127.
38. Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009;4: e6635.
39. Vieth R. Enzyme kinetics hypothesis to explain the U-shaped risk curve for prostate cancer vs. 25- hydroxyvitamin D in Nordic countries. Int J Cancer 2004; 111:468. Letter. (Pubitemid 38998832)
40. Kimlin MG, Olds WJ, Moore MR. Location and vitamin D synthesis: is the hypothesis validated by geophysical data? J Photochem Photobiol B 2007;86:234-239. (Pubitemid 46170221)